Selective effects of nitric oxide on the disposition of chlorzoxazone and dextromethorphan in isolated perfused rat livers

Drug Metabolism and Disposition

Volumn 34, Issue 7, 2006, Pages 1160-1166

  Vuppugalla, Ragini ^a   Mehvar, Reza ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORZOXAZONE; CYTOCHROME P450 2D1; CYTOCHROME P450 3A2; DEXTROMETHORPHAN; DEXTRORPHAN; ISOSORBIDE DINITRATE; MORPHINAN DERIVATIVE; NITRIC OXIDE; NITROPRUSSIDE SODIUM; NORLEVORPHANOL; UMBELLIFERONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BILE; BILIARY EXCRETION; CONTROLLED STUDY; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DISPOSITION; DRUG EFFECT; INHIBITION KINETICS; LIVER; LIVER MICROSOME; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ALCOHOL OXIDOREDUCTASES; ANIMALS; CHLORZOXAZONE; CYTOCHROME P-450 CYP2E1; DEXTROMETHORPHAN; DEXTRORPHAN; ENZYME INHIBITORS; GLUCURONOSYLTRANSFERASE; ISOSORBIDE DINITRATE; KINETICS; LIVER; MALE; NITRIC OXIDE DONORS; NITROPRUSSIDE; PERFUSION; RATS; RATS, SPRAGUE-DAWLEY; UMBELLIFERONES;

EID: 33745235545     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.105.009050     Document Type: Article

References (32)

1. Baaske DM, Smith MD, Karnatz N, and Carter JE (1981) High-performance liquid chromatographic determination of sodium nitroprusside. J Chromatogr 212:339-346.
2. Bogan DP and O'Kennedy R (1996) Simultaneous determination of coumarin, 7-hydroxycoumarin and 7-hydroxycoumarin glucuronide in human serum and plasma by high-performance liquid chromatography. J Chromatogr B Biomed Appl 686:267-273.
3. Chen L and Yang CS (1996) Effects of cytochrome P450 2E1 modulators on the pharmacokinetics of chlorzoxazone and 6-hydroxychlorzoxazone in rats. Life Sci 58:1575-1585.
4. Chen Z, Somogyi A, and Bochner F (1990) Metabolism of dextromethorphan in the rat. Clin Exp Pharm Physiol Suppl 17:11.
5. Conney AH and Burns JJ (1960) Biochemical pharmacological considerations of zoxazolamine and chlorzoxazone metabolism. Ann N Y Acad Sci 86:167-177.
6. Court MH, Von Moltke LL, Shader RI, and Greenblatt DJ (1997) Biotransformation of chlorzoxazone by hepatic microsomes from humans and ten other mammalian species. Biopharm Drug Dispos 18:213-226.
7. Feelisch M (1998) The use of nitric oxide donors in pharmacological studies. Naunyn-Schmiedeberg's Arch Pharmacol 358:113-122.
8. Gergel D, Misik V, Riesz P, and Cederbaum AI (1997) Inhibition of rat and human cytochrome P4502E1 catalytic activity and reactive oxygen radical formation by nitric oxide. Arch Biochem Biophys 337:239-250.
9. Ghezzi P, Saccardo B, Villa P, Rossi V, Bianchi M, and Dinarello CA (1986) Role of interleukin-1 in the depression of liver drug metabolism by endotoxin. Infect Immun 54:837-840.
10. Jayyosi Z, Knoble D, Muc M, Erick J, Thomas PE, and Kelley M (1995) Cytochrome P-450 2E1 is not the sole catalyst of chlorzoxazone hydroxylation in rat liver microsomes. J Pharmacol Exp Ther 273:1156-1161.
11. Kawashima Y, Hagiwara M, Inoue Y, and Someya T (2002) Evaluation of dextromethorphan N-demethylation activity as a biomarker for cytochrome P450 3A activity in man. Pharmacol Toxicol 90:82-88.
12. Kerry NL, Somogyi AA, Mikus G, and Bochner F (1993) Primary and secondary oxidative metabolism of dextromethorphan. In vitro studies with female Sprague-Dawley and Dark Agouti rat liver microsomes. Biochem Pharmacol 45:833-839.
13. Khatsenko OG, Gross SS, Rifkind AB, and Vane JR (1993) Nitric oxide is a mediator of the decrease in cytochrome P450-dependent metabolism caused by immunostimulants. Proc Natl Acad Sci USA 90:11147-11151.
14. Killard AJ, O'Kennedy R, and Bogan DP (1996) Analysis of the glucuronidation of 7-hydroxycoumarin by HPLC. J Pharm Biomed Anal 14:1585-1590.
15. Ling S and Jamali F (2005) Effect of early phase adjuvant arthritis on hepatic p450 enzymes and pharmacokinetics of verapamil: an alternative approach to the use of an animal model of inflammation for pharmacokinetic studies. Drug Metab Dispos 33:579-586.
16. Minamiyama Y, Takemura S, Imaoka S, Funae Y, Tanimoto Y, and Inoue M (1997) Irreversible inhibition of cytochrome P450 by nitric oxide. J Pharmacol Exp Ther 283:1479-1485.
17. Morgan ET (1997) Regulation of cytochromes P450 during inflammation and infection. Drug Metab Rev 29:1129-1188.
18. Paine MJI, McLaughlin LA, Flanagan JU, Kemp CA, Sutcliffe MJ, Roberts GCK, and Wolf CR (2003) Residues glutamate 216 and aspartate 301 are key determinants of substrate specificity and product regioselectivity in cytochrome P450 2D6. J Biol Chem 278:4021-4027.
19. Pang K and Rowland M (1977) Hepatic clearance of drugs. I. Theoretical considerations of a "well-stirred" model and a "parallel tube" model. Influence of hepatic blood flow, plasma and blood cell binding and the hepatocellular enzymatic activity on hepatic drug clearance. J Pharmacokinet Biopharm 5:625-653.
20. Peter R, Bocker R, Beaune PH, Iwasaki M, Guengerich FP, and Yang CS (1990) Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1. Chem Res Toxicol 3:566-573.
21. Renton KW (2001) Alteration of drug biotransformation and elimination during infection and inflammation. Pharmacol Ther 92:147-163.
22. Renton KW (2004) Cytochrome p450 regulation and drug biotransformation during inflammation and infection. Curr Drug Metab 5:235-243.
23. Riddick DS, Lee C, Bhathena A, Timsit YE, Cheng P-Y, Morgan ET, Prough RA, Ripp SL, Miller KKM, Jahan A, et al. (2004) Transcriptional suppression of cytochrome P450 genes by endogenous and exogenous chemicals. Drug Metab Dispos 32:367-375.
24. Sewer MB and Morgan ET (1998) Down-regulation of the expression of three major rat liver cytochrome P450s by endotoxin in vivo occurs independently of nitric oxide production. J Pharmacol Exp Ther 287:352-358.
25. Song IS, Lee IK, Chung SJ, Kim SG, Lee MG, and Shim CK (2002) Effect of nitric oxide on the sinusoidal uptake of organic cations and anions by isolated hepatocytes. Arch Pharm Res (NY) 25:984-988.
26. Vuppugalla R and Mehvar R (2005) Enzyme-selective effects of nitric oxide on affinity and maximum velocity of various rat cytochromes P450. Drug Metab Dispos 33:829-836.
27. Vuppugalla R and Mehvar R (2004a) Hepatic disposition and effects of nitric oxide donors: rapid and concentration-dependent reduction in the cytochrome P450-mediated drug metabolism in isolated perfused rat livers. J Pharmacol Exp Ther 310:718-727.
28. Vuppugalla R and Mehvar R (2004b) Short-term inhibitory effects of nitric oxide on cytochrome P450-mediated drug metabolism: time dependency and reversibility profiles in isolated perfused rat livers. Drug Metab Dispos 32:1446-1454.
29. Warren GW, Poloyac SM, Gary DS, Mattson MP, and Blouin RA (1999) Hepatic cytochrome P-450 expression in tumor necrosis factor-alpha receptor (p55/p75) knockout mice after endotoxin administration. J Pharmacol Exp Ther 288:945-950.
30. Wink DA, Osawa Y, Darbyshire JF, Jones CR, Eshenaur SC, and Nims RW (1993) Inhibition of cytochromes P450 by nitric oxide and a nitric oxide-releasing agent. Arch Biochem Biophys 300:115-123.
31. Witherow LE and Houston JB (1999) Sigmoidal kinetics of CYP3A substrates: an approach for scaling dextromethorphan metabolism in hepatic microsomes and isolated hepatocytes to predict in vivo clearance in rat. J Pharmacol Exp Ther 290:58-65.
32. Yu A and Haining RL (2001) Comparative contribution to dextromethorphan metabolism by cytochrome P450 isoforms in vitro: can dextromethorphan be used as a dual probe for both CYP2D6 and CYP3A activities? Drug Metab Dispos 29:1514-1520.